Atara Biotherapeutics(ATRA) - 2024 Q2 - Quarterly Results

Financial Performance - Atara Biotherapeutics reported total revenues of $28.6 million for Q2 2024, a significant increase of $27.6 million compared to $1.0 million in Q2 2023[10] - Atara Biotherapeutics reported total revenue of $28.64 million for the three months ended June 30, 2024, compared to $957,000 for the same period in 2023, representing a significant increase[22] - Atara reported a net loss of $19.0 million, or $3.10 per share, for Q2 2024, compared to a net loss of $71.1 million, or $16.91 per share, for the same period in 2023[10] - The company incurred a net loss of $19.05 million for the three months ended June 30, 2024, compared to a net loss of $71.11 million for the same period in 2023, indicating improved financial performance[22] Cash and Investments - Cash, cash equivalents, and short-term investments totaled $35.3 million as of June 30, 2024, down from $46.2 million as of March 31, 2024[9] - Cash and cash equivalents increased to $31.31 million as of June 30, 2024, up from $25.84 million as of December 31, 2023[18] - The company has a cash runway projected to fund operations into 2027, contingent on the timing and receipt of potential milestone payments[16] Research and Development - Research and development expenses decreased to $33.3 million in Q2 2024 from $56.1 million in Q2 2023, reflecting a reduction of approximately 41%[10] - Research and development expenses for the three months ended June 30, 2024, were $33.33 million, down from $56.14 million for the same period in 2023[22] - Atara expects to initiate a Phase 1 study of ATA3219 for systemic lupus erythematosus in Q4 2024, with initial clinical data anticipated in mid-2025[4] - Initial clinical data from the ATA3219 non-Hodgkin's lymphoma study is expected in Q1 2025[2] - Atara plans to expand the Phase 1 study of ATA3219 to include a cohort for severe systemic lupus erythematosus without lymphodepletion in Q4 2024[5] - Atara is advancing its AlloCAR-T programs, including ATA3219 and ATA3431, with ongoing clinical trials and regulatory submissions expected in the near future[16] Milestones and Regulatory Updates - The company received a $20 million milestone payment from Pierre Fabre in August 2024 following the acceptance of the tab-cel BLA, with a potential additional $60 million contingent upon FDA approval[3] - The BLA for tab-cel has been granted Priority Review with a PDUFA action date of January 15, 2025[3] Assets and Liabilities - Total current assets decreased to $62.41 million as of June 30, 2024, from $101.87 million as of December 31, 2023[18] - Total liabilities decreased to $228.15 million as of June 30, 2024, from $264.74 million as of December 31, 2023[19] - The company reported a significant increase in accounts payable, rising to $5.25 million as of June 30, 2024, compared to $3.68 million as of December 31, 2023[19] - Atara's accumulated deficit increased to $2.02 billion as of June 30, 2024, compared to $1.97 billion as of December 31, 2023[19] Operating Expenses - The company anticipates full-year 2024 operating expenses to decrease by approximately 35% from 2023 levels[11]